<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-five patients with systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> and severe <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> were treated with 20-80 mg <z:chebi fb="14" ids="7772">omeprazole</z:chebi> daily for up to 5 years </plain></SENT>
<SENT sid="1" pm="."><plain>Efficacy of treatment was assessed by symptom score, by endoscopic and histopathological surveillance of the oesophageal and gastric mucosa, and by laboratory screening including serum gastrin concentration </plain></SENT>
<SENT sid="2" pm="."><plain>Statistically significant relief of symptoms and healing of <z:e sem="disease" ids="C0014868" disease_type="Disease or Syndrome" abbrv="">oesophagitis</z:e> confirmed the efficacy of this treatment </plain></SENT>
<SENT sid="3" pm="."><plain>However, complete healing of <z:e sem="disease" ids="C0014868" disease_type="Disease or Syndrome" abbrv="">oesophagitis</z:e> was not achieved in half of the patients due to residual gastro-oesophageal <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Repeated adjustments of the maintenance dose of <z:chebi fb="14" ids="7772">omeprazole</z:chebi> may be needed for this group of patients </plain></SENT>
<SENT sid="5" pm="."><plain>From the safety point-of-view, nothing was observed to discourage the long-term use of <z:chebi fb="14" ids="7772">omeprazole</z:chebi> in this group of patients </plain></SENT>
</text></document>